Back to Search
DAVID SIEMANN, DO
DO
Family Medicine Physician
NPI: 1417693441IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
DOSR-561-0(HI)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
ROCKY VISTA UNIVERSITY COLLEGE OF OSTEOPATHIC MED
Class of 2022
Research & Publications (20)
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
PMID 19528456·Anticancer Res·2009
7-preclinical
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas.
PMID 19252749·Transl Oncol·2009
8-other
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
PMID 19236265·Expert Opin Investig Drugs·2009
6-review
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
PMID 19215823·Int J Radiat Oncol Biol Phys·2009
7-preclinical
Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy.
PMID 19119958·Am J Vet Res·2009
7-preclinical
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.
PMID 18566400·J Immunol·2008
7-preclinical
Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines.
PMID 18764694·Am J Vet Res·2008
7-preclinical
Characterizing the tumor response to treatment with combretastatin A4 phosphate.
PMID 17448875·Int J Radiat Oncol Biol Phys·2007
7-preclinical
Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
PMID 17451938·Eur J Cancer·2007
7-preclinical
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
PMID 17178843·Cancer Res·2006
6-review
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
PMID 16956760·Eur J Cancer·2006
7-preclinical
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
PMID 16818709·Clin Cancer Res·2006
7-preclinical
Current development status of small-molecule vascular disrupting agents.
PMID 16784022·Curr Opin Investig Drugs·2006
6-review
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
PMID 16751064·Int J Radiat Oncol Biol Phys·2006
7-preclinical
Evaluations of the renal cell carcinoma model Caki-1 using a silicon based microvascular casting technique.
PMID 16417401·Technol Cancer Res Treat·2006
7-preclinical
Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trial.
PMID 15937906·Cancer·2005
3-trial
The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
PMID 15936569·Int J Radiat Oncol Biol Phys·2005
7-preclinical
Differentiation and definition of vascular-targeted therapies.
PMID 15701823·Clin Cancer Res·2005
6-review
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
PMID 15519796·Int J Radiat Oncol Biol Phys·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 98-1005 MOANALUA RD SPC 3030
AIEA, HI 96701 - Phone
- (808) 627-3235
Quick Facts
- NPI
- 1417693441
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile